The model showed strong discriminatory performance, with a time-dependent AUC of 0.69 for the prophylaxis strategy and 0.85 ...

Several studies have indicated a correlation between the number of platelet transfusions received by newborn intensive care unit (NICU) patients and the mortality rate. The number of platelet ...

The Food and Drug Administration recently approved two novel thrombopoiesis-stimulating agents, Romiplostim (AMG-531, Nplate) and Eltrombopag (Promacta), for the treatment of adults with immune ...

Neonatal alloimmune thrombocytopenia is a rare but potentially life threatening condition in newborns. It can cause bleeding in the brain and long-term effects. Treatment usually involves a platelet ...

While thrombocytopenia and bleeding are events that often occur together in neonates, this may not signify cause and effect. In fact, one study reported that 91% of neonates with low platelet counts ...

Neonatal alloimmune thrombocytopenia (NAIT) is a disorder that affects pregnant people and their fetuses. It occurs when the birthing parent’s immune system produces antibodies that attack and destroy ...

Abstract and Introduction Review of Normal Platelet Physiology and Megakaryocytopoisis Qualitative Platelet Abnormalities Conclusion References Nitric oxide (NO) is another drug used in the neonatal ...

-- Data Support Potential Use of an Anti-HPA-1a Antibody as Prophylaxis for FNAIT -- -- In March 2023, Rallybio Announced Clinical Proof-of-Concept Achieved for its Lead Product Candidate, RLYB212, a ...

Japanese researchers may be one step closer to improving treatments for bleeding disorders. A group of researchers from the University of Tokyo has devised a way to maximize the numbers and function ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe ...